# 2025-11793: FDA Gives Specialized Cancer-Test Technology a New Regulatory Lane

2025-11793, Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11793
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11793
- Title: Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27231
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Gives Specialized Cancer-Test Technology a New Regulatory Lane

## Summary

The FDA is officially classifying a special test that spots chromosome problems in blood cancer patients as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the test is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on June 26, 2025, and could save time and money for companies making these tests.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the fluorescence in situ hybridization-based detection of chromosomal abnormalities from patients with hematologic malignancies into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the fluorescence in situ hybridization-based detection of chromosomal abnormalities from patients with hematologic malignancies' classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Class II classification speeds patient access: benefit, medium. The FDA officially classified fluorescence in situ hybridization (FISH) tests for chromosomal abnormalities in hematologic malignancies as Class II (special controls) effective June 26, 2025 (classification applicable December 21, 2018). The Agency says this classification provides reasonable assur…
- New predicate enables easier 510(k) pathway: benefit, medium. Because FDA classified this FISH test via the De Novo process, the device can serve as a predicate for future devices of the same type, allowing other sponsors to use the less-burdensome 510(k) premarket notification process rather than a premarket approval (PMA). This change is described as reduci…
- Manufacturers must meet detailed validation rules: cost, medium. Manufacturers must meet Class II special controls including detailed design verification and validation. Explicit requirements include: analytical sensitivity data with a minimum of 25 specimens from karyotypically normal males; analytical specificity data with a minimum of 5 such specimens; precis…
- Labeling and lab responsibilities required: mixed, medium. Labeling must state: "The test is not intended for use as a stand-alone diagnostic, disease screening, or as a companion diagnostic." The labeling must show performance study results and acceptance criteria, and must include limiting statements that results be interpreted by a qualified pathologist…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11793 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11793/medical-devices-hematology-and-pathology-devices-classification-of-the-fluorescence-in-situ)
- [2025-11793 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11793.pdf)

## Related
- [Previous: 2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Atten…](https://policyrisk.com/federal-register/2025-11791)
- [Next: 2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Her…](https://policyrisk.com/federal-register/2025-11794)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11793 (as of 2026-11-05).
